Methylphenidate (MPH) is widely used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. However, concerns persist about its potential to induce psychotic symptoms, including hallucinations.
Objective:
This study aimed to evaluate the association between MPH exposure and psychotic symptoms in children and adolescents using VigiBase®, the World Health Organization global pharmacovigilance database.
Methods:
We conducted a retrospective, observational study using disproportionality analysis on reports from children and adolescents (5–17 years) exposed to MPH and other ADHD drugs (amitriptyline, atomoxetine, clomipramine, clonidine, desipramine, guanfacine, and nortriptyline). Multivariate logistic regression was used to calculate adjusted reporting odds ratios (aRORs) of psychotic symptoms in MPH-exposed children and adolescents.
Results:
Among 1,992 cases of psychotic symptoms, 1,232 were MPH-associated, with 51.7% classified as serious; significant disproportionalities were observed for the overall age range (aROR = 1.27; 95% confidence intervals [CI]: 1.15–1.40) and the 5–11 (children) age group (aROR = 1.35; 95%CI: 1.19–1.53). Of 1,250 hallucination cases, 809 were MPH-associated, with 59.2% serious; significant disproportionalities were found for the entire age range (aROR = 1.35; 95% CI: 1.19–1.52) and the children age group (aROR = 1.43; 95% CI: 1.23–1.67). The most common type of hallucination was visual (43.2%). MPH discontinuation or dose reduction led to a significantly higher rate of symptom abatement (88.6% of cases) compared to those without these measures (12.0%) (p < .001).
Conclusions:
These results suggest that MPH exposure in children is associated with an increased probability of serious psychotic symptoms, including hallucinations, which typically resolve with discontinuation or dose reduction. Further research is needed to better understand the MPH-induced psychotic symptoms.
Aguilera-AlbesaS, Yoldi-PetriME, Molins-CastiellaT, et al.Hallucinations caused by the introduction of methylphenidate at low doses. Rev Neurol, 2010; 51:254–255.
3.
AktepeE, ErdoganY. Methylphenidate-induced visual hallucinations in a child with autism spectrum disorder and ADHD: A case report. Anadolu Psikiyatri Derg, 2017; 18:1–56.
4.
BachmannCJ, WijlaarsLP, KalverdijkLJ, et al.Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol, 2017; 27(5):484–493; doi: 10.1016/j.euroneuro.2017.03.002
5.
BarkleyR. Hyperactive Children: Handbook for Diagnosis and Treatment. Guilford Press: New York; 1981.
6.
BjörkenstamE, PierceM, BjörkenstamC, et al.Attention Deficit/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ADHD medication and comorbidity, and sibling comparison. Schizophr Res, 2020; 218:124–130; doi: 10.1016/j.schres.2020.01.021
7.
BloomAS, RussellLJ, WeisskopfB, et al.Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry, 1988; 27(1):88–89; doi: 10.1097/00004583-198801000-00013
8.
BorodaA, AkhterR. Hallucinations in a child: A case demonstrating the pitfalls of urine dipstick drug testing. J Forensic Leg Med, 2008; 15(3):198–199; doi: 10.1016/j.jflm.2007.07.003
9.
CherlandE, FitzpatrickR. Psychotic side effects of psychostimulants: A 5-year review. Can J Psychiatry, 1999; 44(8):811–813; doi: 10.1177/070674379904400810
10.
CollertonD, BarnesJ, DiederichNJ, et al.Understanding visual hallucinations: A new synthesis. Neurosci Biobehav Rev, 2023; 150:105208; doi: 10.1016/j.neubiorev.2023.105208
11.
CoskunM, ZorogluS. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol, 2008; 28(6):723–725; doi: 10.1097/JCP.0b013e31818ce752
12.
CorteseS. Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder. N Engl J Med, 2020; 383(11):1050–1056; doi: 10.1056/NEJMra1917069
13.
CorteseS, HoltmannM, BanaschewskiT, et al.; European ADHD Guidelines Group. Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry, 2013; 54(3):227–246; doi: 10.1111/jcpp.12036
14.
DemeulemeesterM, KochmanF, FligansB, et al.Assessing early-onset hallucinations in the touch-screen generation. Br J Psychiatry, 2015; 206(3):181–183; doi: 10.1192/bjp.bp.114.154153
15.
DungalH, GriffithsDE. Visual hallucinations induced by a sympathomimetic drug. Can Med Assoc J, 1984; 131(10):1186.
16.
EkinciO, GunesS, EkinciN. Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate. Anadolu Psikiyatri Derg, 2017:1; doi: 10.5455/apd.227212
17.
EsnafogluE, DemirEY. Hallucination and priapism associated with methylphenidate usage: Two case reports. Indian J Psychiatry, 2017; 59(3):386–387; doi: 10.4103/psychiatry.IndianJPsychiatry_273_16
18.
EvansSJW, WallerPC, DavisS. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf, 2001; 10(6):483–486; doi: 10.1002/pds.677
FaraoneSV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev, 2018; 87:255–270; doi: 10.1016/j.neubiorev.2018.02.001
21.
FusaroliM, SalvoF, BegaudB, et al.The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf, 2024; 47(6):585–599; doi: 10.1007/s40264-024-01423-7
22.
GolinkoB. Side effects of dextroamphetamine and methylphenidate in hyperactive children: A brief review. Prog Neuropsychopharmacol Biol Psychiatry, 1984; 8(1):1–8; doi: 10.1016/0278-5846(84)90129-5
HamshereML, StergiakouliE, LangleyK, et al.Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry, 2013; 203(2):107–111; doi: 10.1192/bjp.bp.112.117432
26.
HesapciogluS, HesapciogluST, GokerZ, et al.Methylphenidate Induced Psychotic Symptoms: Two Cases Report. J Med Cases, 2013; 4:106–108; doi: 10.4021/jmc923w
27.
HollisC, ChenQ, ChangZ, et al.Methylphenidate and the risk of psychosis in adolescents and young adults: A population-based cohort study. Lancet Psychiatry, 2019; 6(8):651–658; doi: 10.1016/S2215-0366(19)30189-0
28.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Introductory Guide for Standardised MedDRA Queries (SMQs), Version 25.0. ICH: Geneva; 2022.
29.
IrmakA, Ince-TasdelenB, OzmenS, et al.Treatment choice in association of attention deficit hyperactivity disorder with Williams and Moebius Syndromes: Case reports. Bull Clin Psychopharmacol, 2014; 24:226.
KrinzingerH, HallCL, GroomMJ, et al.; ADDUCE Consortium. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev, 2019; 107:945–968; doi: 10.1016/j.neubiorev.2019.09.023
32.
LindquistM. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information J, 2008; 42(5):409–419; doi: 10.1177/009286150804200501
ManKK, CoghillD, ChanEW, et al.Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry, 2016; 6(11):e956; doi: 10.1038/tp.2016.216
35.
Martínez-AguayoJC, ArancibiaM, Meza-ConchaN, et al.Brief psychosis induced by methylphenidate in a child with attention deficit disorder: A case report and literature review. Medwave, 2017; 17(5):e6980; doi: 10.5867/medwave.2017.05.6980
36.
Medice. Medikinet®: Summary of product characteristics. Medice: Iserlohn; 2023.
37.
MinoY, AokiS. Methylphenidate-induced psychosis in an adolescent with hyperkinetic disorder. Kawasaki Med J, 1999; 25:81–85.
38.
MontastrucJL, SommetA, BagheriH, et al.Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol, 2011; 72(6):905–908; doi: 10.1111/j.1365-2125.2011.04037.x
39.
MozzicatoP. MedDRA: An overview of the medical dictionary for regulatory activities. Pharm Med, 2009; 23(2):65–75; doi: 10.1007/BF03256752
40.
NahlerG. Dictionary of Pharmaceutical Medicine. Springer: Vienna; 2009; doi: 10.1007/978-3-211-89836-9_64
41.
National institute for health and clinical excellence. Attention deficit hyperactivity disorder: diagnosis and management. National Institute for Health and Clinical Excellence: London; 2019.
42.
NeyPG. Psychosis in a child, associated with amphetamine administration. Can Med Assoc J, 1967; 97:1026–1029.
43.
Novartis. Ritalin®: Summary of product characteristics. Novartis: Basel; 2023.
44.
O’HareK, ByrneJF, RamsayH, et al.Stimulant medication use and risk of psychotic experiences. Pediatrics, 2025; 155:e2024069142; doi: 10.1542/peds.2024-069142
45.
PatadiaVK, SchuemieMJ, ColomaP, et al.Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm, 2015; 37(1):94–104; doi: 10.1007/s11096-014-0044-5
46.
PliszkaS, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 2007; 46(7):894–921; doi: 10.1097/chi.0b013e318054e724
RamstadE, StorebøOJ, GernerT, et al.Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: A Cochrane systematic review with meta-analysis and trial sequential analysis. Scand J Child Adolesc Psychiatr Psychol, 2018; 6(1):52–71; doi: 10.21307/sjcapp-2018-003
49.
RashidJ, MitelmanS. Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry, 2007; 46(8):945–946; doi: 10.1097/CHI.0b013e318067fd7c
50.
RossRG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry, 2006; 163(7):1149–1152; doi: 10.1176/ajp.2006.163.7.1149
51.
SankeyRJ, NunnAJ, SillsJA. Visual hallucinations in children receiving decongestants. Br Med J (Clin Res Ed), 1984; 288(6427):1369; doi: 10.1136/bmj.288.6427.1369
52.
SauderKL, BradyWJ, HennesH. Visual hallucinations in a toddler: Accidental ingestion of a sympathomimetic over-the-counter nasal decongestant. Am J Emerg Med, 1997; 15(5):521–526; doi: 10.1016/s0735-6757(97)90200-x
53.
SchranteeA, TammingaHG, BouzianeC, et al.Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: A randomized clinical trial. JAMA Psychiatry, 2016; 73(9):955–962; doi: 10.1001/jamapsychiatry.2016.1572
ShyuYC, YuanSS, LeeSY, et al.Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res, 2015; 168(1–2):161–167; doi: 10.1016/j.schres.2015.08.033
56.
StahlSM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press: Cambridge; 2021.
57.
StorebøOJ, StormMRO, Pereira RibeiroJ, et al.Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev, 2023; 3(3):CD009885; doi: 10.1002/14651858.CD009885.pub3
58.
SurlesLK, MayHJ, GarryJP. Adderall-induced psychosis in an adolescent. J Am Board Fam Pract, 2002; 15:498–500.
59.
Tomas VilaM, Izquierdo QuevedoFJ, Cerdan VeraMT, et al.Visual hallucinations caused by methylphenidate. An Pediatr, 2010; 72:229–230; doi: 10.1016/j.anpedi.2009.10.013
60.
TostH, AlamT, Meyer-LindenbergA. Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev, 2010; 34(5):689–700; doi: 10.1016/j.neubiorev.2009.06.005
61.
TregunnoPM, FinkDB, Fernandez-FernandezC, et al.Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf, 2014; 37(4):249–258; doi: 10.1007/s40264-014-0146-y
62.
YoungJ. Methylphenidate-induced hallucinosis: Case histories and possible mechanisms of action. J Dev Behav Pediatr, 1981; 2(2):35–38.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
